announces acceptance of FDA IND for BP2202. Enables US Phase I clinical trial initiation for iPSC-derived BCMA CAR-NKT cell therapy, aiming to administer the first patient within the year. Impact on fiscal year ending March 2027 is unknown, but advancement of the clinical development platform is expected to enhance long-term corporate value.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4594","jir_company_name":"BrightPath Biotherapeutics Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4594-20260803-01.pdf","jir_short_summary":" announces acceptance of FDA IND for BP2202. Enables US Phase I clinical trial initiation for iPSC-derived BCMA CAR-NKT cell therapy, aiming to administer the first patient within the year. Impact on fiscal year ending March 2027 is unknown, but advancement of the clinical development platform is expected to enhance long-term corporate value.","jir_summary":"### Summary of development progress\nWe announced the FDA IND acceptance for BP2202, stating that a US Phase I clinical trial for relapsed\/refractory multiple myeloma using BP2202 can commence. BP2202 uses an off-the-shelf, iPSC-derived CAR-NKT cell therapy, with the aim of reaching the first patient dosing within the year. We plan to accelerate clinical development and advance manufacturing, quality testing, and facility readiness for the investigational drug.\n\n### Financial impact and outlook\nThis milestone is not expected to directly affect the 2027 fiscal year results; it is positioned as an important milestone to build the long-term clinical platform and foundation. While the IND acceptance indicates development progress, specifics on use of funds and market impact are not currently known.","jir_financial_highlights":"Direct disclosure of impact period \/ financial metrics: Unknown (Unknown)","jir_category":"","jir_hashtags":"#BrightPathBio, #BP2202, #Biotech","jir_key_figures":"BP2202: FDA IND acceptance (US Phase I trial initiation possible)\nFirst patient dosing target: within the year\nImpact on FY2027 results: Unknown (no impact stated)","jir_meta_title":"BrightPath Bio Announces FDA IND Acceptance for BP2202 | August 2026","jir_meta_description":"BrightPath Bio announces FDA IND acceptance for BP2202. Aims to begin US Phase I trial with first patient dosing within the year. Direct impact on FY2027 results is unknown.","jir_og_title":"BrightPath Bio Announces FDA IND Acceptance for BP2202","jir_og_description":"IND acceptance for BP2202 enables US Phase I trial initiation; aims for first patient dosing within the year.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59787,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-92432","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n